Monoclonal Antibodies: Producing Magic Bullets by Somatic Cell Hybridization

Molecular Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1892, Building 10, Room 11N311, Bethesda, MD 20892-1892, USA.
The Journal of Immunology (Impact Factor: 4.92). 04/2005; 174(5):2451-2. DOI: 10.4049/jimmunol.174.5.2451
Source: PubMed
Download full-text


Available from: David H Margulies,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fusions of dendritic cells (DC) and tumor cells are increasingly used in tumor immunotherapy. The strategy for DC-tumor fusion vaccine is based on the fact that DC are the most potent antigen-presenting cells in the body, whereas tumor cells express abundant tumor antigens. The fusion of these two cell types creates a heterokaryon with both DC-derived costimulatory molecules, efficient antigen-processing and -presentation machinery, and tumor-derived antigens. In animal and human studies, fusion-cell (FC) vaccines have been shown to possess the elements essential for processing and presenting tumor antigens to host immune cells, for inducing effective immune response, and for breaking T-cell tolerance to tumor-associated antigens. Moreover, FC vaccines provide protection against challenge with tumor cells and mediate regression of established tumors. Despite these unique features of DC-tumor fusion cells and the observation of tumor eradication in animal studies, only limited, yet encouraging, success has been seen in clinical trials. This chapter describes the methods used for preparation of DC-tumor fusion cells, summarizes the effect of FC in stimulating T cell responses, analyzes factors influencing the success or failure of FC-mediated immunotherapy and discusses recent advances in concept and techniques of DC-tumor fusions. KeywordsAntitumor immunity-cancer-cell-cell fusion-dendritic cell-fusion cell vaccine-immune therapy
    01/1970: pages 315-350;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Crohn's disease is a complex multifactorial disorder characterized by the alternation of a cytokine-driven T-lymphocyte-depending inflammation of the intestinal mucosa, and "off" periods, where patients are completely asymptomatic. Although all the causative factors have not been clearly identified, the continuously growing understanding of the major abnormalities of the inflammatory and immune response leading to the often debilitating symptoms reported by Crohn's disease patients, improves our capacity to characterize new potential therapeutic targets with the subsequent hope to discover new (more efficient and less toxic) drugs. Saying that, in the recent years, tumor necrosis factor-alpha undoubtedly emerges as a key cytokine involved in Crohn's disease pathogenesis, and constant efforts have been made to control tumor necrosis factor-alpha deleterious effects in Crohn's disease. This review schematically summarizes the current understanding of tumor necrosis factor-alpha's role in Crohn's disease pathogenesis as well as the present and the future treatment strategies which may be helpful in patients by inhibiting tumor necrosis factor-alpha production and effects. Beside drugs under investigation, several original approaches are described or mentioned, most of them leading to recent patents such as polyclonal anti-TNF-alpha antibodies from avian origin, allowing potentially oral administration, or combination strategies such as vitamin D and anti-TNF-alpha antibodies or methotrexate and anti-TNF-alpha antibodies, or decoy oligodeoxynucleotides interfering with the binding of nuclear factor-kappaB to its target genes promoters.
    Recent Patents on Inflammation & Allergy Drug Discovery 02/2007; 1(1):21-34. DOI:10.2174/187221307779815093
  • [Show abstract] [Hide abstract]
    ABSTRACT: A rapid and efficient method for preparing monoclonal antibody (MAb) serotypes using Neisseria meningitidis outer membrane were used in BALB/c mouse footpads for the immunization. The popliteal lymph nodes were isolated 19 days later for MAb-producing hybridomas, from which the MAbs against the 37 kDa protein were screened. Variations in class 2/3 (PorB) proteins form the basis for meningococcal serotyping. This is the first report on the preparation of MAbs against N. meningitidis that is specific to PorB protein using popliteal lymph nodes. The new monoclonal antibodies were specific for PorB outer membrane protein FL24(PL)Br, a new serotype 24 class 3 antigens of non-typeable (NT:NST) serogroup B strain, and FL14(PL)Br specific for the serotype 14, and reacted with the S3446 reference strain analyzed. A total of 12% of the case isolates reacted with one or more of the monoclonal antibodies. The high-affinity MAbs produced by hybridoma methodology provide a basis for further research on the pathogenesis and early diagnosis of meningococcus.
    Hybridoma (2005) 11/2007; 26(5):302-10. DOI:10.1089/hyb.2007.0508 · 0.34 Impact Factor
Show more